Exclusive worldwide license agreement for preclinical ROR1 ADC, on track to submit IND in 1Q 2025 -
This document is hosted externally.
Unless the owner has removed it from the web, you can access the full document via its original URL:
https://www.bioadvance.com/media/010824-Immunome-Exclusively-Licenses-Zentalis-ROR1-Antibody-Drug-Conjugate-and-Proprietary-Technology-Platform.pdfUnless the owner has removed it from the web, you can access the full document via its original URL:
See similar contracts (4)
Alternatively, you can try searching for similar contracts:
